Book Chapters / Books

Queen's University ITS will be performing network maintenance on Saturday, August 19 beginning at 12 am and lasting until approximately 5 am EDT. 

Access to services that are physically housed on campus, such EDC, Mango and the main Canadian Cancer Trials Group website will NOT be available from off campus through the maintenance period.

  • Wagner S, Dancey J. Potential Future Indication of Rapamycin Analogs for the Treatment of Solid Tumors. In: Mita M, Mita A, Rowinsky EK, eds. mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer-Verlag Paris, p. 229-249, 2016.
  • Hilton J, Bradbury PA, Dancey J. Predictive Biomarkers for Epidermal Growth Factor Receptor Agents in Non-Small Cell Lung Cancer. In: Yang SX, Dancey JE, eds. Handbook of Therapeutic Biomarkers in Cancer. Pan Standford Publishing, p. 155-182, 2013.
  • Monzon JG, Dancey J. Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. In: Yang SX, Dancey JE, eds. Handbook of Therapeutic Biomarkers in Cancer. Pan Standford Publishing, p. 183-232, 2013.
  • Yang SX, Dancey JE. Overview: Theraperutic Biomarkers in Cancer. In: Yang SX, Dancey JE, eds. Handbook of Therapeutic Biomarkers in Cancer. Pan Standford Publishing, p. 1-29, 2013.
  • Monson JG, Dancey J. Combination Agents Versus Multi-Targeted Agents - Pros and Cons. In: Morphy JR, Harris CJ, eds. Designing Multi-Target Drugs. RSC Publishing, p. 155-180, 2012.
  • Parulekar W, Sargent D. Principles of Anticancer Drug Development, Cancer Drug Discovery and Development: Phase III Clinical Trials with Anticancer Agents, October 2010. In: p. 163-188, 2010.
  • Parulekar W, Eisenhauer E, Gelber R. Principles of Clinical Trials. In: Textbook of Medical Oncology. p. 56-76, 2009.
  • Manual for Clinical Trials Nursing. 2nd ed. Editors: Klimaszewski AD, Bacon M, Deininger HE, Ford BA, Westendorp JG, Oncology Nursing Society, 2008.
  • Wagner S, Dancey JE. Inhibiting the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway. In: Soria J-C, Giaccone G, eds. Targeted Therapies in Oncology. CRC Press, p. 65-83, 2007.
  • Eisenhauer EA, Twelves C, Buyse M. Phase I Cancer Clinical Trials: A Practical Guide. 1st ed. Oxford University Press, p. 1-343, 2006.
  • Parulekar W. Neoplastic Diseases. In: du Souich P, Orme M, Erill S, eds. The IUPHAR Compendium of Basic Principles for Pharmacological Research in Humans. IUPHAR, p. 338-351, 2004.
  • Tu D. Minimization Procedure. In: Chow SC, ed. Encyclopaedia of Biopharmaceutical Statistics. New York: Marcel Dekker, Inc., p. 614-618, 2003.
  • Tu D. Odds Ratio. In: Chow SC, ed. Encyclopaedia of Biopharmaceutical Statistics. New York: Marcel Dekker, Inc., p. 678-684, 2003.
  • Tu D. Canadian Health Products and Food Branch and Therapeutic Products Directorate. In: Chow SC, ed. Encyclopaedia of Biopharmaceutical Statistics. New York: Marcel Dekker, Inc., p. 147-151, 2003.
  • Voskoglou-Nomikos T, Baral S, Seymour L. The role of in vitro cell line, human xenograft and mouse allograft models in cancer drug development. In: Budman DR, Calvert AH, Rowinsky EK, eds. Anticancer Drug Development in Handbook of Anticancer Drug Development. Baltimore: Lippincott Williams & Wilkins, p. 129-147, 2003.
  • Gluck S, Crump M, Stewart D, Arnold A, Couban S, Kirkbride P, Levine E, O'Reilly S, Pritchard K, Smith A, Tu D, Dancey J, Marlin S, Shepherd L. Summary of current studies in breast cancer using high-dose chemotherapy and autologous blood cell transplantation, including NCIC CTG MA.16. In: Dicke KA, Keating A, eds. Autologous Blood & Marrow Transplantation X. Charlottesville, Virginia: Carden Jennings Publishing, p. 106-112, 2001.
  • Pater J. Dose Intensity Analysis. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology. New York: Marcel Dekker Inc., 2001.
  • Zee B, Osoba D. Health-related Quality of Life Outcomes. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology. New York: Marcel Dekker Inc., 2001.
  • Manual for Clinical Trials Nursing. 1st ed. Editors: Klimaszewski A, Aikin J, Bacon M, DiStasio S, Ehrenberger H, Ford B, Pittsburgh, PA: Oncology Nursing Press, Inc., 2000.
  • Sargent D, Zee B, Milan C, Torri V, Francini G. Meta-analysis of Individual Patient Survival Data Using Random Effect Models. In: Berry & Stangl, ed. Meta-Analysis in Medicine and Health Policy. New York: Marcel Dekker Inc., 2000.
  • Osoba D, Zee B, Sadura A, Pater J, Quirt I. Measurement of quality of life in an adjuvant trial of gamma-interferon versus levamisole in malignant melanoma. In: Salmon SE, ed. Adjuvant Therapy of Cancer VII. J.B. Lippincott Co., p. 412-416, 1993.
  • Willan A, Warr D, Pater J, Levitt M, Erlichman C, Osoba D. Methodological issues in anti-emetic studies. In: Effect of Cancer on Quality of Life. CRC Press, Inc., 1991.
  • Zee B, Pater J. Statistical analysis of trials assessing quality of life. In: Osoba D, ed. Effect of Cancer on Quality of Life. Boca Raton, CRC Press, Inc., p. 113-124, 1991.
  • Eisenhauer E, Swenerton KD, Sturgeon JFG, Fine S, O'Reilly S, Canetta R. Carboplatin therapy for recurrent ovarian carcinoma. NCI Canada experience and a review of the literature. In: Bunn PA, Canetta R, Ozols RF, Rozencweig M, eds. Carboplatin (JM-8) Current Perspectives and Future Directions. W.B. Saunders Co., p. 133-140, 1990.
  • Eisenhauer E, Mackillop W. Focus on clinical trials. In: Stoll BA, ed. Cost/Benefit Controversies in Cancer Treatment. United Kingdom: The Macmillan Press Ltd., 1988.
  • Eisenhauer E. Tumour necrosis factor -- A brief review. In: Cancer in Ontario 1987. OCTRF, 1988.
  • Pater J. Design and organization of clinical trials. Section 1, Epidemiology and trial design. In: Ovarian Cancer -- the Way Ahead. Royal College of Obstetricians and Gynaecologists, 1987.
  • Stewart T, Shelley A, Willan A, Hollinshead A. An evaluation of the role of tumor-specific antigens. In: Lung Cancer: Current Status and Prospects for the Future. Annual Clinical Conference on Cancer. Austin: University of Texas System Cancer Center, p. 351-374, 1986.